Back to search

Netherlands· NL-9f6bd33ff058

Mepact, poeder voor suspensie voor intraveneuze infusie, 4 mg

A mifamurtid product containing mifamurtide 1-water, registered in Netherlands by Esteve Pharmaceuticals S.A.. The same ATC class is registered in 8 of our 19 countries.

ATC L03AX15

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedMepact, poeder voor suspensie voor in…ATCL03AX15REGISTER NO.NL-9f6bd33ff058PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Mifamurtid is registered in 8 of 19 countries.

Countries holding a registration under ATC L03AX15 (mifamurtid), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose

Mifamurtid · ATC L03AX15

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MIFAMURTIDE 1-WATER
Manufacturer
Esteve Pharmaceuticals S.A.
Country
Netherlands (NL)
ATC code
L03AX15
ATC class
Mifamurtid
Defined daily dose
0.7 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/08/502

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mifamurtid in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mifamurtid products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Mepact
  • Liechtenstein · Mepact
  • Norway · Mepact

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c361df07-b2cb-4c94-9f74-2f811973b8f2
GET /v1/drugs/c361df07-b2cb-4c94-9f74-2f811973b8f2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor suspensie voor injectie",
  "route": null,
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Mifamurtide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp73583",
  "excipients": [
    "DIOLEOYL PHOSPHATIDYL SERINE SODIUM (RI)",
    "PALMITOYL-OLEOLYLFOSFATIDYLCHOLINE (RI)"
  ],
  "substances": [
    "MIFAMURTIDE 1-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2009/03/06",
  "procedure_number": "EMEA/H/C/000802",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/08/502",
  "additional_monitoring": "N"
}

See everything about mifamurtid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.